iMDK

CAS No. 881970-80-5

iMDK( —— )

Catalog No. M28701 CAS No. 881970-80-5

iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 115 Get Quote
10MG 177 Get Quote
25MG 410 Get Quote
50MG 605 Get Quote
100MG 860 Get Quote
500MG 1728 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    iMDK
  • Note
    Research use only, not for human use.
  • Brief Description
    iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
  • Description
    iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.(In Vitro):Administration of iMDK (50-500 nM) for 72 h quarterhydrate suppressed AKT phosphorylation in H441 lung adenocarcinoma cells after treatment dose-dependently. In contrast, iMDK quarterhydrate robustly increases p-ERK.(In Vivo):Intraperitoneally injection with 100 μl of iMDK ( (9 mg/kg/day) and ; oral administion of PD0325901 (5 mg/kg) effectively reduced lung tumor growth in a xenograft mouse model.
  • In Vitro
    Cell Viability Assay Cell Line:H441 (lung adenocarcinoma; KRASG12V), H2009 (non-small cell carcinoma; KRASG12A), A549 (lung carcinoma; KRASG12S) and H520 (lung squamous cell carcinoma; KRASWT) Concentration:iMDK (2.5 μM) and PD0325901 (0.5 μM) for H441 and H2009 cells iMDK (0.125 μM) and PD0325901 (0.25 μM) for H520 cells iMDK (0.25 μM) and PD0325901 (0.125 μM) for A549 cells Incubation Time:72 hours Result:iMDK alone did not inhibit cell viability of A549 cells, the combinatorial treatment of iMDK with PD0325901 significantly inhibited that of A549 cells compared to the single treatment of PD0325901.Western Blot Analysis Cell Line:H441 lung adenocarcinoma cells Concentration:0-500 nM Incubation Time:72 hours Result:Suppressed AKT phosphorylation in a dose-dependent manner.ERK1/2 phosphorylation was increased.
  • In Vivo
    Animal Model:female BALB/c nude mice (6 week old) bearing H441 human lung cancer xenografts Dosage:iMDK (9 mg/kg) and PD0325901 (5 mg/kg) Administration:Intraperitoneally injected with 100 μL iMDK everyday and/or orally administered PD0325901 five times per week (on days 1, 2, 3, 4, 5, 7, 8, 9, 10, 11)Result:Reduced significantly volume of the tumors derived from H441 lung adenocarcinoma cells after the combination treatment with iMDK and PD0325901 compared to that of single compound in a xenograft mouse model.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    TRPV1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    881970-80-5
  • Formula Weight
    376.41
  • Molecular Formula
    C21H13FN2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 3.33 mg/mL (8.85 mM)
  • SMILES
    Fc1ccc(Cc2cn3cc(nc3s2)-c2cc3ccccc3oc2=O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Gomtsyan A, et al. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem. 2008 Feb 14;51(3):392-5.
molnova catalog
related products
  • PI-103 hydrochloride

    A potent, dual class I PI3K/mTOR inhibitor with IC50 of 2/3/3/15/ for p110α/β/δ/γ, respectively.

  • GNE-490

    GNE-490 is a potent, selective, orally available class I PI3K inhibitor.

  • CYH33 methanesulfona...

    CYH33 (CYH-33) is a novel potent, PI3Kα-selective inhibitor with IC50 of 5.9 nM/598 nM/ 78.7 nM/225 nM aginst class I PI3K isoform α/β/δ/γ, respectively.